Table 4.
Characteristics of each patient with HZ reactivation after getting COVID‐19 vaccine
| Variables | AIIRDs patients | |||||
|---|---|---|---|---|---|---|
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
| Gender | Female | Female | Female | Female | Female | Female |
| Age | 69 | 60 | 47 | 32 | 70 | 25 |
| BMI (Kg/m2) | 22.2 | 26.3 | 22.5 | 22.0 | 20.0 | 30.7 |
| AIIRDs disease | SpA | RA | SLE | SLE | SpA | SLE |
| Comorbidities | DM | Hyperlipidemia | None | None | DM | None |
| Medications | / | JAK inhibitor | Steroid, 5 mg/d; HCQ, MMF | Steroid, 2.5 mg/d, MMF | / | Steroid, 2.5 mg/d; HCQ; MMF |
| Rheumatologist consulting before vaccination | No | No | Yes | Yes | No | No |
| Medication adjustment before vaccination | No | No | No | No | No | No |
| Disease activity | Stable | Aggravation | Stable | Aggravation | Stable | Stable |
| Time to VZV onset after vaccination, days | 10 | 90 | 30 | 3 | 10 | 120 |
| Vaccination dose associated with rash | Third | Third | Third | Second | Third | Second |
| Diagnosis department | Community hospital | Other departments | Dermatology | Clinic | Community hospital | Rheumatology |
| Rash location | Abdomen | Back | Buttocks | Face | Abdomen | Vaccinated arm |
| Treatments | Acyclovir; Pregabalin | Acyclovir; Gabapentin | Valaciclovi | Acyclovir | Valaciclovi; Pregabalin | Valaciclovi; Gabapentin |
| Rash durations, days | 13 | 30 | 20 | 7 | 15 | 30 |
| Postherpetic neuralgia | Yes | Yes | Yes | No | Yes | Yes |
| Vaccine type | Sinopharm [Vero Cell]‐Inactivated COVID‐19 vaccination | Sinovac COVID‐19 Vaccine (Vero Cell), Inactivated | Sinopharm/WIBP | Sinopharm/WIBP | Sinopharm [Vero Cell]‐Inactivated COVID‐19 vaccination | Zhifei Longcom |
| Prior history of Herpes Zoster | No | Yes | No | Yes | No | No |
| Get vaccination of Varicella zoster vaccine | Yes | No | No | No | No | No |
| Get vaccination of Herpes zoster vaccine | No | No | No | No | No | No |
Abbreviations: AIIRDs, Autoimmune inflammatory rheumatic diseases; BMI, Body Mass Index; DM, Diabetes mellitus; HCQ, Hydroxychloroquine; MMF, Mycophenolate mofetil; RA, Rheumatoid arthritis; SLE, Systemic lupus erythematosus; SPA, Spondyloarthritis.